Ito Hiroyuki, Nakayama Haruhiko, Murakami Shuji, Yokose Tomoyuki, Katayama Kayoko, Miyata Yoshihiro, Okada Morihito
Department of Thoracic Surgery, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan.
Department of Thoracic Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241-8515, Japan.
Gen Thorac Cardiovasc Surg. 2017 Sep;65(9):512-518. doi: 10.1007/s11748-017-0790-0. Epub 2017 Jun 7.
We studied whether histologic subtype according to the new IASLC/ATS/ERS adenocarcinoma classification influences the extent of resection in patients with pathological stage IA lung adenocarcinoma.
Data on 288 patients with pathological stage IA lung adenocarcinoma were analyzed retrospectively. Recurrence-free survival (RFS) rates were compared according to clinicopathological characteristics, including predominant histologic subtype and extent of resection.
Median follow-up was 38.9 months. Lobectomy was performed in 146 patients, and sublobar resection in 142 patients. When recurrence was compared among the low-grade group (adenocarcinoma in situ, AIS; minimally invasive adenocarcinoma, MIA), intermediate-grade group (lepidic, acinar, and papillary) and high-grade group (solid and micropapillary), the RFS rate decreased as the grade increased (p = 0.037). There was no recurrence in the low-grade or lepidic predominant groups. The recurrence pattern did not differ according to the type of resection or histological subtype. Even in the intermediate- and high-grade groups, the extent of resection was not significantly related to the RFS rate (p = 0.622, p = 0.516). The results were unchanged after adjusting for independent risk factors. The concordance rate between clinical and pathological stage IA was good in low (98.6%) and intermediate grade (84.6%) and poor in high grade (41.2%).
AIS, MIA, and lepidic predominant may be curable by any type of complete resection. Even in invasive subtypes, lobectomy does not offer a recurrence-free advantage over sublobar resection. However, in the high-grade group, less than half of clinical stage IA was actually pathological stage IA. Physicians should exercise caution whenever sublobar resection is planned.
我们研究了根据国际肺癌研究协会(IASLC)/美国胸科学会(ATS)/欧洲呼吸学会(ERS)新的腺癌分类的组织学亚型是否会影响病理分期为IA期的肺腺癌患者的切除范围。
对288例病理分期为IA期的肺腺癌患者的数据进行回顾性分析。根据临床病理特征,包括主要组织学亚型和切除范围,比较无复发生存(RFS)率。
中位随访时间为38.9个月。146例患者接受了肺叶切除术,142例患者接受了肺段以下切除术。当比较低级别组(原位腺癌,AIS;微浸润腺癌,MIA)、中级别组(贴壁型、腺泡型和乳头型)和高级别组(实体型和微乳头型)的复发情况时,RFS率随级别升高而降低(p = 0.037)。低级别组或贴壁型为主的组中无复发。复发模式根据切除类型或组织学亚型无差异。即使在中级别和高级别组中,切除范围与RFS率也无显著相关性(p = 0.622,p = 0.516)。在调整独立危险因素后结果不变。IA期临床和病理分期之间的一致性在低级别(98.6%)和中级别(84.6%)中良好,在高级别(41.2%)中较差。
AIS、MIA和贴壁型为主的腺癌通过任何类型的完全切除可能治愈。即使在浸润性亚型中,肺叶切除术相对于肺段以下切除术也没有无复发优势。然而,在高级别组中,不到一半的临床IA期实际上是病理IA期。每当计划进行肺段以下切除时,医生应谨慎行事。